Eli Lilly and Company launched its Alzheimer's drug, Donanemab, in India under the brand name Lormalzi. India's Central Drugs Standard Control Organization granted marketing authorization for the treatment. The drug targets patients with mild cognitive impairment or mild dementia.
Medical professionals will administer the therapy as a monthly intravenous infusion. The treatment removes amyloid plaques in the brain associated with Alzheimer's progression.
The United States approved the therapy last year. Eli Lilly views India as a potential manufacturing and export hub. The drug will be commercially available in India later this month.